-
Effects of Losartan on Cardiovascular Morbidity and Mortality in
Patients with Isolated Systolic Hypertension and LVH; Increase in
Nocturnal Blood Pressure and Progression to Microalbuminuria in Type 1
Diabetes; HRT, Lipid, and Glucose Metabolism in Diabetic and
Nondiabetic Postmenopausal Women; Effects of Long-Term Treatment With
ACE Inhibitors in the Presence or Absence of Aspirin; Long-Term Risks
Associated with Atrial Fibrillation: 20-Year Follow-up of the
Renfrew/Paisley Study; Olfactory Impairment in Older Adults
-
FDA Approves Claritin For OTC Use For Seasonal Rhinitis; Simpler Atrial Fibrillation Management; Oral Anticoagulation Vs Aspirin in AF; Immunization Does Not Cause Autism; Statins May Lower CRP Levels; Simvastatin Reduced CRP Plasma Levels; FDA Actions
-
Aripiprazole (Abilify), a new drug for schizophrenia, received FDA approval November 15; on November 14, Neurocrine Biosciences Inc. announced positive results from its first phase III clinical trial with indiplon-IR achieving primary and secondary end points of sleep initiation.
-
The results of 3 recent investigations suggest that immunotherapy still has the potential to become a treatment for AD but that the road to its successful development is likely to be a long one.
-
In this thoughtful, well-balanced review, Clarke and Guttman review the evidence for using new dopamine agonists to treat patients with early PD.
-
-
-
The multicenter, unsustained tachycardia trial (MUSTT) was a randomized clinical trial designed to test whether antiarrhythmic therapy guided by electrophysiologic testing would reduce arrhythmic death and total mortality in high-risk patients.
-
Iwai and colleagues evaluated the effects of adenosine in 42 patients who underwent an electrophysiologic study and radiofrequency ablation for recurrent atrial tachycardias.
-
The pravastatin in elderly individuals at risk of vascular disease (PROSPER) trial is a study of statin therapy in high-risk elderly individuals. PROSPER tested the hypothesis that the benefits of statin therapy on cardiovascular disease, stroke, and cognitive decline would be seen in the elderly, which had not yet been rigorously investigated with respect to LDL lowering with a statin.
